
Breaking the Mold: Acumen Pharmaceuticals Unveils Revolutionary Trial Screening Techniques with pTau217 Assay for Early Alzheimer’s Disease at Prestigious Conference
Welcome to the Future of Alzheimer’s Disease Research Acumen Pharmaceuticals, Inc. Presents Groundbreaking Data at CTAD Conference Hey there, all you brainy individuals! Have you heard the latest buzz in the world of Alzheimer’s disease research? Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has just dazzled us with some fresh data at the 17th Annual Clinical Trials…